PBYI
Puma Biotechnology Inc

6,859
Mkt Cap
$311.36M
Volume
340,267.00
52W High
$7.68
52W Low
$2.58
PE Ratio
10.02
PBYI Fundamentals
Price
$6.12
Prev Close
$6.15
Open
$6.14
50D MA
$6.52
Beta
0.95
Avg. Volume
487,410.74
EPS (Annual)
$0.6142
P/B
2.37
Rev/Employee
$1.28M
$230.31
Loading...
Loading...
News
all
press releases
Wall Street Zen Upgrades Puma Biotechnology (NASDAQ:PBYI) to Strong-Buy
Wall Street Zen upgraded Puma Biotechnology from a "buy" rating to a "strong-buy" rating in a research report on Saturday...
MarketBeat·2d ago
News Placeholder
More News
News Placeholder
Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why
PBYI stock drops over 9% as weak 2026 revenue guidance and heavy reliance on Nerlynx raise concerns despite modest sales growth.
Zacks·4d ago
News Placeholder
IRWD vs. PBYI: Which Small-Cap Biotech Stock Is a Better Buy?
Ironwood and Puma Biotechnology are developing GI and cancer therapies, respectively, with sales of their sole drugs expected to support 2026 revenues.
Zacks·10d ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Upgraded at Wall Street Zen
Wall Street Zen upgraded Puma Biotechnology from a "hold" rating to a "buy" rating in a report on Sunday...
MarketBeat·15d ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Stock Rating Lowered by Wall Street Zen
Wall Street Zen downgraded Puma Biotechnology from a "buy" rating to a "hold" rating in a research note on Saturday...
MarketBeat·23d ago
News Placeholder
PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View
Puma Biotechnology Q4 earnings top estimates with 28% revenue jump, but weak 2026 outlook sparks 14% after-hours plunge.
Zacks·23d ago
News Placeholder
Puma Biotechnology Q4 Earnings Call Highlights
Puma Biotechnology (NASDAQ:PBYI) reported fourth-quarter 2025 total revenue of $75.5 million, driven by NERLYNX product revenue and a sharp increase in royalty revenue, according to management's...
MarketBeat·24d ago
News Placeholder
Puma Biotechnology (NASDAQ:PBYI) Announces Earnings Results
Puma Biotechnology (NASDAQ:PBYI - Get Free Report) issued its earnings results on Thursday. The biopharmaceutical company reported $0.29 earnings per share (EPS) for the quarter, topping the...
MarketBeat·24d ago
News Placeholder
Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates
Puma Biotech (PBYI) delivered earnings and revenue surprises of +20.83% and +11.26%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·24d ago
News Placeholder
Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2025. Unless otherwise stated, all comparisons are...
Business Wire·24d ago
<
1
2
...
>

Latest PBYI News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.